New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP

• Published in: Oncogenesis (New York, NY) Vol. 9; no. 8; p. 73
• Main Authors: Mhaidly, Rana, Krug, Adrien, Gaulard, Philippe, Lemonnier, François, Ricci, Jean-Ehrland, Verhoeyen, Els
• Format: Journal Article
• Language: English
• Published: United States Nature Publishing Group 14.08.2020; Nature Publishing Group UK
• Subjects: Animal models; Cell culture; Lymphocytes T; Lymphoma; Malignancy; Phenotypes; Review; T-cell lymphoma; Transcription; Tumor cells; Tumor microenvironment
• ISSN: 2157-9024; 2157-9024
• DOI: 10.1038/s41389-020-00259-x

Mouse models are essential to study and comprehend normal and malignant hematopoiesis. The ideal preclinical model should mimic closely the human malignancy. This means that these mice should recapitulate the clinical behavior of the human diseases such as cancer and therapeutic responses with high reproducibility. In addition, the genetic mutational status, the cell phenotype, the microenvironment of the tumor and the time until tumor development occurs, should be mimicked in a preclinical model. This has been particularly challenging for human angioimmunoblastic lymphoma (AITL), one of the most prominent forms of peripheral T-cell lymphomas. A complex network of interactions between AITL tumor cells and the various cells of the tumor microenvironment has impeded the study of AITL pathogenesis in vitro. Very recently, new mouse models that recapitulate faithfully the major features of human AITL disease have been developed. Here, we provide a summary of the pathology, the transcriptional profile and genetic and immune-phenotypic features of human AITL. In addition, we give an overview of preclinical models that recapitulate more or less faithfully human AITL characteristics and pathology. These recently engineered mouse models were essential in the evaluation of novel therapeutic agents for possible treatment of AITL, a malignancy in urgent need of new treatment options.